Merck KGaA is to acquire Silence Therapeutics, a biotechnology company developing precision engineered medicines using siRNA technology. Merck has agreed to acquire Silence in an all-cash transaction with an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion. “We are pleased to have reached this agreement with Merck KGaA, Darmstadt, Germany, […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!